---
layout: default
title: Teplizumab
parent: Model Prediction Only (L5)
nav_order: 759
evidence_level: L5
indication_count: 10
---

# Teplizumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Teplizumab: From Type 1 Diabetes to Diabetic Cataract

## One-Sentence Summary

> Teplizumab (Tzield) is an anti-CD3 monoclonal antibody used to delay the onset of Stage 3 Type 1 Diabetes by modulating pathogenic T-cells.
> TxGNN predicts it may be effective for **Diabetic Cataract**, but this candidate has **zero clinical trials** and **zero publications** supporting it.
> The model's own mechanistic rationale flags this as a likely knowledge-graph artifact rather than a true biological link — 9 of the top 10 predicted indications for this drug are cataract subtypes or unrelated rare diseases, all clustering around a shared "diabetes" node.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Type 1 Diabetes Mellitus (delay of clinical onset) — per Tzield indication referenced in evidence rationale; no Canadian regulatory record exists |
| Predicted New Indication | Diabetic Cataract |
| TxGNN Prediction Score | 98.38% |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, a formal mechanism of action record is not available in the drug-level data (marked as a data gap). However, the model's own repurposing rationale describes Teplizumab as an anti-CD3 monoclonal antibody that modulates pathogenic T-cells to slow autoimmune β-cell destruction — this is the basis of its approved use in delaying Stage 3 Type 1 Diabetes.

Diabetic cataract, however, is driven by a distinct and unrelated pathology: chronic hyperglycemia causes sorbitol accumulation in the lens via the polyol pathway, leading to osmotic swelling and oxidative stress on lens fibers. This is a metabolic/structural process, not an autoimmune, T-cell-mediated one.

The evidence pack's own mechanistic assessment concludes that the high TxGNN score is most likely explained by a shared "diabetes" node in the knowledge graph connecting Teplizumab to a cluster of cataract subtypes (diabetic, immature, mature, nuclear senile, cortical, senile), rather than a genuine causal or pharmacological relationship. The same pattern repeats for several other top-ranked candidates (e.g., craniostenosis cataract, tetanic cataract, antithrombin deficiency type 2), which have no plausible biological connection to CD3-targeted immunomodulation at all — a strong signal of embedding-space false positives.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Canada Market Information

Teplizumab has no Health Canada market authorization on record — the product is not currently marketed in Canada (0 DINs, 0 active licenses).

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: internal review flagged a **Blocking** data gap — Health Canada/TFDA package insert warnings and contraindications are not yet retrieved, which prevents this candidate from advancing to a formal S1 safety pre-assessment.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate rests entirely on an L5 (model-only) prediction with no supporting clinical trials or literature, and the mechanistic rationale itself identifies the score as a likely knowledge-graph artifact from a shared "diabetes" node rather than a genuine anti-CD3 → lens pathology pathway. A blocking safety data gap (missing package insert warnings/contraindications) also prevents formal S1 review.

**To proceed, the following is needed:**
- Health Canada/TFDA package insert (warnings, contraindications) — resolves blocking gap DG001
- Confirmed mechanism of action documentation via DrugBank API — resolves gap DG002
- Independent preclinical or mechanistic evidence directly linking CD3-targeted T-cell modulation to lens/cataract pathophysiology
- If none emerges, treat this and the other cataract-cluster predictions (ranks 2–9) as low-priority/likely false positives rather than pursuing further evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

